Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Current Oncology Reports
|
April 30, 2026
Clinical Development of Novel-Novel Multi-Company Combination Therapies in Oncology
Patrick Y Muller, Johannes Eisinger, Pakeeza Sayyed, et al.
Drug Discovery Today
|
May 4, 2016
Secondary pharmacology: screening and interpretation of off-target activities - focus on translation
Steven Whitebread, Berengere Dumotier, Duncan Armstrong, et al.
Anticancer Research
|
August 15, 2002
Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam
Zuzana Dobbie, Patrick Y Muller, Karl Heinimann, et al.
Atherosclerosis
|
July 18, 2002
Sterol-regulatory element-binding protein (SREBP)-2 contributes to polygenic hypercholesterolaemia
André R Miserez, Patrick Y Muller, Luca Barella, et al.
Drug Discovery Today
|
September 24, 2018
Safety differentiation: emerging competitive edge in drug development
Marianne Uteng, Laszlo Urban, Dominique Brees, et al.
Mabs
|
April 28, 2010
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
Frank R Brennan, Laura Dill Morton, Sebastian Spindeldreher, et al.
Anticancer Research
|
January 18, 2003
Overexpression of Wnt target genes in adenomas of familial adenomatous polyposis patients
Daniel D'Orazio, Patrick Y Muller, Karl Heinimann, et al.
Biochimica Et Biophysica Acta
|
May 26, 2004
Identification of hepatic molecular mechanisms of action of alpha-tocopherol using global gene expression profile analysis in rats
Luca Barella, Patrick Y Muller, Manfred Schlachter, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Current Oncology Reports
|
April 30, 2026
Clinical Development of Novel-Novel Multi-Company Combination Therapies in Oncology
Patrick Y Muller, Johannes Eisinger, Pakeeza Sayyed, et al.
Drug Discovery Today
|
May 4, 2016
Secondary pharmacology: screening and interpretation of off-target activities - focus on translation
Steven Whitebread, Berengere Dumotier, Duncan Armstrong, et al.
Anticancer Research
|
August 15, 2002
Expression of COX-2 and Wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam
Zuzana Dobbie, Patrick Y Muller, Karl Heinimann, et al.
Atherosclerosis
|
July 18, 2002
Sterol-regulatory element-binding protein (SREBP)-2 contributes to polygenic hypercholesterolaemia
André R Miserez, Patrick Y Muller, Luca Barella, et al.
Drug Discovery Today
|
September 24, 2018
Safety differentiation: emerging competitive edge in drug development
Marianne Uteng, Laszlo Urban, Dominique Brees, et al.
Mabs
|
April 28, 2010
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
Frank R Brennan, Laura Dill Morton, Sebastian Spindeldreher, et al.
Anticancer Research
|
January 18, 2003
Overexpression of Wnt target genes in adenomas of familial adenomatous polyposis patients
Daniel D'Orazio, Patrick Y Muller, Karl Heinimann, et al.
Biochimica Et Biophysica Acta
|
May 26, 2004
Identification of hepatic molecular mechanisms of action of alpha-tocopherol using global gene expression profile analysis in rats
Luca Barella, Patrick Y Muller, Manfred Schlachter, et al.
Page
of 2